BeOne Medicines

Latest news

• ONC Maintained by JP Morgan -- Price Target Raised to $445 (opens in a new tab)

  GuruFocus · Oct 1, 2026

• BeOne Medicines (NASDAQ:ONC) Stock Price Target Raised at JPMorgan Chase & Co. (opens in a new tab)

  MarketBeat · Oct 1, 2026

• BeOne Medicines price target raised to $445 from $425 at JPMorgan (opens in a new tab)

  TipRanks · Oct 1, 2026

• Biotech Leader BeOne Medicines Poised To Hit Early Buy Points (opens in a new tab)

  Investor's Business Daily · Oct 1, 2026

• BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock Has Consensus Target Price of $402.71 (opens in a new tab)

  MarketBeat · Oct 1, 2026

• Form 144 BEONE MEDICINES LTD. For: 1 October By Investing.com (opens in a new tab)

  Investing.com Canada · Oct 1, 2026

• Form 4 BeOne Medicines Ltd. For: 1 October By Investing.com (opens in a new tab)

  Investing.com Canada · Oct 1, 2026

• BeOne Medicines (NASDAQ:ONC) Insider Sells $11,318,704.12 in Stock (opens in a new tab)

  MarketBeat · Sep 30, 2026

• After exercising options, BeOne Medicines (ONC) scientific advisory chair sold 31,028 depositary shares. (opens in a new tab)

  Stock Titan · Sep 30, 2026

• An officer proposes selling $407K in vested stock grants at BeOne Medicines (ONC). (opens in a new tab)

  Stock Titan · Sep 30, 2026

• BeOne Medicines Ltd (6160) Receives a Buy from DBS (opens in a new tab)

  The Globe and Mail · Sep 29, 2026

• BeOne Medicines Advances BGB-58067 Tablet Study, Sharpening Early-Stage Investor Focus (opens in a new tab)

  TipRanks · Sep 28, 2026

• Josh Schwartz Marks His Final Day at BeOne Medicines (opens in a new tab)

  Oncodaily · Sep 27, 2026

• BeOne Medicines (ONC) Rebrand Puts Its Growth Story In Focus On A Higher Fair Value (opens in a new tab)

  Simply Wall Street · Sep 26, 2026

• BeOne Medicines Advances Phase 3 Liver Cancer Trial With BGB-B2033 (opens in a new tab)

  TipRanks · Sep 23, 2026

• Sonrotoclax Safety Study Completion Signals Next Steps for BeOne Medicines (opens in a new tab)

  TipRanks · Sep 21, 2026

• ONC Q2 2026 Earnings: Reported EPS of $13.84 as Shares Edge Lower - Earnings Volatility Report (opens in a new tab)

  dars.gov.et · Sep 21, 2026

• BeOne Medicines (ONC) insiders exercise options for 30,768 ADS (opens in a new tab)

  Stock Titan · Sep 18, 2026

• BeOne Medicines at Morgan Stanley conference: brukinsa, pipeline drive growth (opens in a new tab)

  Investing.com UK · Sep 14, 2026

• The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal (opens in a new tab)

  Yahoo Finance · Sep 4, 2026

• BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It? (opens in a new tab)

  Yahoo Finance · Sep 4, 2026

• BeOne (ONC) accounting chief sells ADS to cover RSU taxes (opens in a new tab)

  Stock Titan · Sep 3, 2026

• BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading Range - BPI Bear Correction (opens in a new tab)

  siam.in · Sep 3, 2026